Trials that use: P-values
New to this method? Read the tutorial →
10,701 results
- Erector Spinae Plane vs. Paravertebral Nerve Block for Thoracic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Erector Spinae Plane vs. Paravertebral Nerve Block for Thoracic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03758261).
- EREPIndependent statistical analysis of Emotion Regulation and Emotion Perception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03790878).
- ERGO2Independent statistical analysis of Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ErivedgeIndependent statistical analysis of Vismodegib for Treatment of Basal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01543581).
- Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00970502).
- ERPIndependent statistical analysis of Treatment Response of Geriatric Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00754936).
- Ertugliflozin: Cardioprotective Effects on Epicardial Fat: Complete Statistical AnalysisIndependent statistical analysis of Ertugliflozin: Cardioprotective Effects on Epicardial Fat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04167761).
- EscapeIndependent statistical analysis of Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ESCAPEIndependent statistical analysis of Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ESCAPeIndependent statistical analysis of Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01283009).
- ESCAPEDIndependent statistical analysis of Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Escitalopram Effects on CSF Amyloid Beta: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram Effects on CSF Amyloid Beta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02161458).
- Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05289830).
- ESETTIndependent statistical analysis of Established Status Epilepticus Treatment Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01960075).
- ESkAPEIndependent statistical analysis of Enhancing Skeletal Adaptations to PTH and Exercise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05029128).
- Esmolol for Treatment of Perioperative Tachycardia: Complete Statistical AnalysisIndependent statistical analysis of Esmolol for Treatment of Perioperative Tachycardia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01208402).
- Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery: Complete Statistical AnalysisIndependent statistical analysis of Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery: Complete Statistical AnalysisIndependent statistical analysis of ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05257941).
- ESPRITComplete statistical analysis of ESPRIT, the randomized phase 3 trial of recombinant interleukin-2 in HIV-positive patients receiving antiretroviral therapy, including time-to-event, longitudinal CD4, categorical, safety, and statistical interpretation.
- ESS-NSPASIndependent statistical analysis of A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test: primary endpoint results, effect estimate with confidence interval, sample-size…
- Establishing Efficacy of a Functional-Restoration Based CAM Pain Management Program in Post-9/11 Veterans: Complete Statistical AnalysisIndependent statistical analysis of Establishing Efficacy of a Functional-Restoration Based CAM Pain Management Program in Post-9/11 Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Establishing Functional Biomarkers for Spaced Theta-Burst Stimulation: Complete Statistical AnalysisIndependent statistical analysis of Establishing Functional Biomarkers for Spaced Theta-Burst Stimulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03687892).
- ESTEEMIndependent statistical analysis of Combined Treatment for Mixed Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01959347).
- ESTRELLAIndependent statistical analysis of A Study of Belcesiran in Patients With AATLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04764448).
- Estrogen and Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Estrogen and Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436992).
- Estrogen for Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Estrogen for Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01083641).
- Estrogen Variability and Irritability During the Menopause Transition: Complete Statistical AnalysisIndependent statistical analysis of Estrogen Variability and Irritability During the Menopause Transition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05388656).
- ET-01 in Subjects With Lateral Canthal Lines: Complete Statistical AnalysisIndependent statistical analysis of ET-01 in Subjects With Lateral Canthal Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03326856).
- ETA-TVIndependent statistical analysis of EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02877732).
- Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan): Complete Statistical AnalysisIndependent statistical analysis of Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01230177).
- Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab: Complete Statistical AnalysisIndependent statistical analysis of Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ETDAIndependent statistical analysis of Eustachian Tube Dysfunction Assessment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02667301).
- Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Etirinotecan Pegol (NKTR-102) in NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Etirinotecan Pegol (NKTR-102) in NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01773109).
- Etoposide in Patients With COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Etoposide in Patients With COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04356690).
- Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: Complete Statistical AnalysisIndependent statistical analysis of Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…